Barely Significant
← all excerpts

Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites.

Int J Cancer · 2012 · PMC3415680 · PMID 21702044

Europe PMCDOI
1
hedged sentence
0.0846
closest p · 1.7× alpha
0.0846
boldest claim

The sentences

a positive trendp = 0.0846so close (0.05 < p ≤ 0.1)
OS showed a positive trend for paracentesis plus catumaxomab in the overall (1-year survival rate 10.4% vs . 3.4%; p = 0.0846; HR 0.723), ovarian cancer (1-year survival rate 19.7% vs . 9.0%; p = 0.1543; HR 0.650) and nonovarian cancer (6-month survival rate 17.2% vs . 4.9%; p = 0.4226; HR 0.825) populations and was significantly prolonged in patients with gastric cancer (6-month survival rate 17.3% vs . 0% and median OS 71 vs . 44 days; p = 0.0313; HR 0.469).

also in 6,779 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.